Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from AstraZeneca Pharma India Limited ( (IN:ASTRAZEN) ).
AstraZeneca Pharma India Limited has announced that it received approval from the Central Drugs Standard Control Organisation to import and market Trastuzumab Deruxtecan (Enhertu) for a new indication in India. This approval allows the company to provide treatment for adult patients with unresectable or metastatic HER2-positive solid tumors who have previously undergone systemic treatment and lack satisfactory alternative options, potentially enhancing the company’s market presence in oncology.
More about AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited operates in the pharmaceutical industry, focusing on the development and distribution of prescription medicines. The company is known for its innovative products in various therapeutic areas, including oncology, cardiovascular, renal, and metabolism.
Average Trading Volume: 1,322
Technical Sentiment Signal: Strong Buy
Current Market Cap: 230.5B INR
For a thorough assessment of ASTRAZEN stock, go to TipRanks’ Stock Analysis page.